VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
VTAE was delisted on the 24th of October, 2016.
34 hedge funds and large institutions have $120M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2014 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
550% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 4
168% more capital invested
Capital invested by funds: $45M → $120M (+$75.5M)
127% more funds holding
Funds holding: 15 → 34 (+19)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$1.29M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$1.15M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$883K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.39M |
| 2 |
WT
Wellcome Trust
London,
United Kingdom
|
-$1.17M |
| 3 |
Millennium Management
New York
|
-$918K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$569K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$477K |
VTAE Hedge Fund Activity: Q4 2014 in Review
34 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q4 2014, worth a combined $120M — up 168% from $45M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new VTAE positions and 4 closed out — a net gain of 22 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $15.9M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.39M sold.
- 34 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q4 2014, up from 15 in Q3 2014.
- Funds reported $120M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q4 2014, up 168% quarter-over-quarter.
- 26 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q4 2014 and 4 closed out, a net change of +22 holders.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q4 2014 was Fidelity Investments, an estimated $15.9M added.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q4 2014 was Alyeska Investment Group, an estimated $1.39M sold.
Based on aggregated 13F filings for Q4 2014.